References of "Hiligsmann, Mickaël"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailClinical en economic implications of non-adherence with osteoporosis medications
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Osteoporosis International (2009, March), 20(S1), 16

Detailed reference viewed: 31 (6 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women
Hiligsmann, Mickaël ULg; Neuprez, Audrey ULg; Scholtissen, Sophie et al

in Osteoporosis International (2009, March), 20(S1), 130

Detailed reference viewed: 56 (7 ULg)
Full Text
Peer Reviewed
See detailFRAX(r) and the assessment of fracture probability in men and women from Belgium.
Reginster, Jean-Yves ULg; Devogelaer, Jean-Pierre; Hiligsmann, Mickaël ULg et al

in Osteoporosis International (2009, March), 20(Suppl.1), 38-39

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailGlucosamine sulfate in the treatment of knee osteoarthritis: impact on health utility.
Scholtissen, S.; Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg et al

in Osteoporosis International (2009, March), 20(Suppl.1), 149

Detailed reference viewed: 36 (11 ULg)
Full Text
Peer Reviewed
See detailEffect of glucosamine sulfate on health utility data in patients with knee osteoarthritis : reanalysis of two 3-year prospective studies.
Scholtissen, S.; Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg et al

in Osteoporosis International (2009, March), 20(Suppl.1), 18

Detailed reference viewed: 28 (5 ULg)
Full Text
Peer Reviewed
See detailIbandronate in the management of postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg et al

in Clinical Medicine. Therapeutics (2009), 1

Detailed reference viewed: 41 (11 ULg)
Full Text
Peer Reviewed
See detailEfficacite anti-fracturaire de l'ibandronate administre par voie intraveineuse: de la complexite des etudes epidemiologiques interventionnelles a la pratique quotidienne.
Neuprez, A.; Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg et al

in Revue Médicale de Liège (2009), 64(10), 525-9

Numerous epidemiological approaches are used to demonstrate the efficacy of a new chemical entity. In postmenopausal osteoporosis, anti-fracture efficacy can be assessed through prospective, randomized ... [more ▼]

Numerous epidemiological approaches are used to demonstrate the efficacy of a new chemical entity. In postmenopausal osteoporosis, anti-fracture efficacy can be assessed through prospective, randomized controlled trials, meta-analyses or real-life setting studies. Intravenous ibandronate was recently marketed, with the aim of optimizing drug absorption and adherence to treatment. Furthermore, this new formulation avoids gastrointestinal side effects and constrains linked to the oral intake of the medication. Spinal anti-fracture efficacy of IV ibandronate derives from a non-inferiority bridging study, using surrogate endpoints, i.e., bone mineral density and biochemical markers of bone turnover, compared to the oral daily formulation, previously registered for the treatment of osteoporosis in Europe. Coherent results from two separate meta-analyses have suggested that the non-vertebral anti-fracture efficacy of IV ibandronate is similar to that observed with oral, daily and weekly bisphosphonates. Similarly, a recent real-life setting study, based on claims from an US database, suggests that hip fractures are reduced, with IV ibandronate, to the same extend as they are with oral bisphosphonates. Notwithstanding, those results should probably be confirmed in an European setting, before being extrapolated, in daily practice, to the Belgian population. [less ▲]

Detailed reference viewed: 33 (3 ULg)
Full Text
Peer Reviewed
See detailPoor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
Rabenda, Véronique ULg; Hiligsmann, Mickaël ULg; Reginster, Jean-Yves ULg

in Expert Opinion on Pharmacotherapy (2009), 10(14), 2303-15

Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical ... [more ▼]

Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical outcomes. Studies systematically demonstrated that overall compliance and persistence with OBPs among osteoporotic women are poor. Although extending dosing intervals improved adherence, the gains are suboptimal. Most importantly, low compliance and persistence rates consistently resulted in increased rates of fractures. The results emphasize the importance of adherence to treatment to achieve optimal antifracture efficacy. There is an urgent need to implement strategies and to encourage physicians to take measures that increase patients' awareness of the need to use osteoporosis medications as directed in order to benefit from them fully. [less ▲]

Detailed reference viewed: 67 (8 ULg)
Full Text
Peer Reviewed
See detailImpact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis.
Bruyère, Olivier ULg; Scholtissen, S.; Neuprez, Audrey et al

in Journal of Medical Economics (2009), 12(4), 356-360

Abstract Objectives: The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA ... [more ▼]

Abstract Objectives: The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA) during a 24-month treatment course. The second objective was, using these data, to conduct economic analyses. Methods: Data from the STOPP study was used. This study was a randomised, double-blind, placebo (PL) -controlled trial of 2-year duration. In the STOPP study, authors assessed quality of life using the Western Ontario and McMaster Osteoarthritis Index (WOMAC). WOMAC scores were translated into Health Utility Index (HUI) scores using a specific formula. Incremental cost effectiveness ratio (ICER) was calculated taking into account the cost of CS and its effect on HUI scores, compared to PL. Results: At baseline, the mean (SD) HUI scores were 0.59 (0.17), and 0.59 (0.18) for the PL and CS groups, respectively (p=0.31 between the two groups). The mean (SD) HUI scores changes from baseline to 6 months were 0.02 (0.02), and 0.05 (0.01) for the PL and CS groups, respectively (p=0.03). After 24 months of follow-up, HUI score increases by 0.04 (0.02) in the PL group and by 0.05 (0.02) in the CS group (p=0.37). Using the price bracket of CS in Europe, ICER assessment always resulted in a cost below euro30,000 per QALY gained, after 6, 12 and 24 months of treatment. Conclusion: CS treatment increases health utilities in patients with knee OA compared to PL over the first 6 months of treatment. Economic evaluation based on these data suggests that CS treatment could be considered as cost-effective in patients with knee OA up to a period of 24 months. A limitation in this study is the absence of direct utility assessment as well as the absence of effective treatment as comparator. [less ▲]

Detailed reference viewed: 60 (17 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: new data on fracture prevention and mechanisms of action.
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Neuprez, Audrey et al

in Current Osteoporosis Reports (2009), 7(3), 96-102

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence ... [more ▼]

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence. Strontium ranelate is the first compound to simultaneously decrease bone resorption and stimulate bone formation. Its anti-fracture efficacy at various skeletal sites has been established for as long as 5 years through studies of the highest methodological standards. Increases in bone mineral density observed after 1 year of treatment are predictive of the long-term fracture efficacy, suggesting for the first time in osteoporosis that bone densitometry can be used as a monitoring tool. Due to a positive risk/benefit ratio, strontium ranelate is now considered as a first-line treatment in the management of osteoporosis. [less ▲]

Detailed reference viewed: 37 (1 ULg)
Full Text
Peer Reviewed
See detailLoss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women.
Bruyère, Olivier ULg; Varela, A. R.; Adami, S. et al

in European journal of epidemiology (2009), 24

The objective of the study assess the relationship between bone mineral density (BMD) loss over time and fracture incidence in postmenopausal women. This is a posthoc analysis that includes women from the ... [more ▼]

The objective of the study assess the relationship between bone mineral density (BMD) loss over time and fracture incidence in postmenopausal women. This is a posthoc analysis that includes women from the placebo group of two large randomized controlled trials having assessed the efficacy of a new anti-osteoporotic drug. BMD was assessed every 6 months during 3 years at the lumbar spine, the femoral neck and the total proximal femur. Vertebral fractures were assessed using a semiquantitative method. Hip fractures were based on written documentation. All patients received calcium and vitamin D. In the present study that included 1,775 patients (with complete data at baseline and after 3 years), the logistic regression analysis, adjusted for covariates, showed that 3-year change in lumbar BMD was not statistically associated with the new vertebral fractures after 3 years. However, femoral neck and total proximal femur BMD changes was statistically correlated with the incidence of new vertebral fractures (P < 0.001). When considering change in BMD after the first year of follow-up, a decrease in total proximal femur BMD was statistically associated with an increase in the incidence of new vertebral fractures during the last 2 years of follow-up (P = 0.048). The 3-year change in femoral neck and total proximal BMD was statistically correlated with the incidence of hip and fragility fracture after 3 years (all P < 0.001). In this elderly osteoporotic population receiving calcium and vitamin D, a decrease in hip BMD after 1 or 3 year of follow-up, is associated with an increased risk of fracture incidence. However, spine BMD changes do not influence vertebral fracture incidence. [less ▲]

Detailed reference viewed: 41 (10 ULg)
Full Text
Peer Reviewed
See detailDevelopment and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis.
Hiligsmann, Mickaël ULg; Ethgen, Olivier ULg; Bruyère, Olivier ULg et al

in Value in Health (2009), 12(5), 687-696

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory ... [more ▼]

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory management and versatility. In this article, we describe and validate an original Markov microsimulation model to accurately assess the cost-effectiveness of prevention and treatment of osteoporosis. Methods: We developed a Markov microsimulation model with a lifetime horizon and a direct health-care cost perspective. The patient history was recorded and was used in calculations of transition probabilities, utilities, and costs. To test the internal consistency of the model, we carried out an example calculation for alendronate therapy. Then, external consistency was investigated by comparing absolute lifetime risk of fracture estimates with epidemiologic data. Results: For women at age 70 years, with a twofold increase in the fracture risk of the average population, the costs per quality-adjusted life-year gained for alendronate therapy versus no treatment were estimated at Euro 9105 and Euro 15,325, respectively, under full and realistic adherence assumptions. All the sensitivity analyses in terms of model parameters and modeling assumptions were coherent with expected conclusions and absolute lifetime risk of fracture estimates were within the range of previous estimates, which confirmed both internal and external consistency of the model. Conclusion: Microsimulation models present some major advantages over cohort-based models, increasing the reliability of the results and being largely compatible with the existing state of the art, evidence-based literature. The developed model appears to be a valid model for use in economic evaluations in osteoporosis. [less ▲]

Detailed reference viewed: 224 (32 ULg)
Full Text
Peer Reviewed
See detailImpact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Osteoporosis International (2008, December), 19(S2), 282

Detailed reference viewed: 35 (13 ULg)